Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Business
Marianne Barriaux

Purchase rumours boost Oxford BioMedica

Oxford BioMedica is up 3.75p, or 20%, at 22.5p on rumours drug giant Sanofi Aventis may be interested in buying it.

The biopharmaceutical firm, which specialises in the development and commercialisation of gene-based medicines, is already a partner of the French pharmaceutical group.

Oxford BioMedica has signed a global licensing agreement with Sanofi to develop and commercialise TroVax for the treatment of cancer - a deal worth up to €518m (£385m) if all development and registration targets are met for certain defined indications, in addition to royalties on future sales.

Sanofi will post its full-year results tomorrow and investors might find out more then. The group is known to be keen to get further into biologics. But neither company is commenting so far.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.